Understanding new pharmacologic therapy for type 2 diabetes

Nurse Practitioner

Volumn 24, Issue 6, 1999, Pages 15-27

  Gutowski, Catherine ^a  

^a NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; INSULIN;

ARTICLE; BLOOD; DRUG COMBINATION; GLUCOSE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; NON INSULIN DEPENDENT DIABETES MELLITUS; NURSING;

BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN;

EID: 0033144025     PISSN: 03611817     EISSN: 15388662     Source Type: Journal    
DOI: 10.1080/00006205-199906000-00001     Document Type: Article

References (11)

1. DCCT Research Group: The effect of intensive diabetes treatment on the development and progression of long term complication in insulin-dependent diabetes mellitus. N Engl J iled 1993;329:977-86.
2. Ohkubo Y, Kishikawa H, Araki E, et al.: Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: A randomized prospective 6- year study. Diabetes Res Clin Pract 1995;28:103-17.
3. Nathan DiM: Some answers, more controversy, from UKPDS. Lanect 1998; 352:832-33.
4. American Diabetes Association: Standards of medical care for patients with diabetes mellitus. Diabetes Care 1998;21(1):S23-S31.
5. U.K. Prospective Diabetes Study Group: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and the risk of complications in patients with type 2 diabetes. Lancet 1998;352:837-53.
6. American Diabetes Association: National standards for diabetes selfmanagement education programs and American Diabetes Association review criteria. Diabetes Care 1998;21(1):S95-S98.
7. American Diabetes Association: Clinical Practice Recommendations 1996. The pharmacologic treatment of hyperglycemia in NIDDM. Diabetes Care 1996;19(1):854-861.
8. Sulkin, TV., Bosnian D, Krentz AJ: Contraindications to metformin therapy in patients with NIDDM. Diabetes Care 1997;20(6):925-34.
9. Iwamoto Y, Kosaka K, Kuzuya T, etal.: Effects of Troglitazone. Diabetes Care 1996; 19(2): 151-56.
10. Edelman, SV., Henry, RR., oral Agents. In: Diagnosis and Management of Type 2 Diabetes. Caddo, Okla.: Professional Communications, hie., 1997:57-82.
11. Vlendosa R: Beyond Sulfonylurcas. Diabetes Wellness Letter 1998;4(5):l-4.